PDS Biotechnology Corporation (PDSB) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-89.5%

$0.14

vs $1.37 price

Levered DCF

$0.21

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

-44.34

Distress zone

Rating

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-1.04×	-1.58×	-3.58×	-9.23×	-12.27×	-2.4×	-1.84×	-0.25×
P/B	3.86×	3.13×	5.89×	8.58×	3.28×	1.32×	1.1×	0.04×
P/S	0×	0×	0×	0×	0×	0×	0×	0×
EV / EBITDA	-0.86×	-3.12×	-3.02×	-8.03×	-6.65×	-0.51×	-0.1×	9.38×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	2.98×	2.64×	4.33×	7.79×	17.8×	9.28×	5.18×	5.59×
Debt / equity	1.83×	1.15×	0.91×	0.53×	0.01×	0.02×	0×	0×
Interest coverage	-5.91×	-7.77×	-10.23×	-31.64×	0×	0×	-462.15×	-30.24×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-372.9%	-197.9%	-164.3%	-92.8%	-26.8%	-54.7%	-59.8%	-137.0%
Return on invested capital	-116.5%	-86.9%	-83.4%	-60.0%	-26.6%	-53.7%	-125.7%	-39.7%
Return on assets	-113.1%	-82.9%	-72.3%	-53.1%	-25.2%	-48.1%	-48.3%	-112.8%
Free cash flow yield	-77.7%	-59.0%	-21.9%	-6.8%	-6.0%	-36.7%	-140.1%	-3094.7%
Earnings yield	-96.6%	-63.3%	-27.9%	-10.8%	-8.2%	-41.4%	-54.3%	-3814.9%
Enterprise value	$25.9M	$39.6M	$121.1M	$327.2M	$142.6M	$7.6M	$738.5K	-$33.5M
Net debt / EBITDA	0.32×	1.56×	0.82×	1.24×	3.02×	1.9×	1.68×	9.68×
Cash conversion cycle (days)	0	-10,285	-44,460	0	0	0	-4,442	-2,109